97 related articles for article (PubMed ID: 21034827)
1. MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity.
Girvan RC; Knight DA; O'Loughlin CJ; Hayman CM; Hermans IF; Webster GA
Vaccine; 2011 Jan; 29(3):545-57. PubMed ID: 21034827
[TBL] [Abstract][Full Text] [Related]
2. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
Hornung RL; Longo DL; Gowda VL; Kwak LW
Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
[TBL] [Abstract][Full Text] [Related]
3. Corynebacterium pyruviciproducens promotes the production of ovalbumin specific antibody via stimulating dendritic cell differentiation and up-regulating Th2 biased immune response.
Qingzhen H; Jia T; Shengjun W; Yang Z; Yanfang L; Pei S; Essien BS; Zhaoliang S; Sheng X; Qixiang S; Finegold SM; Xu H
Vaccine; 2012 Feb; 30(6):1115-23. PubMed ID: 22178104
[TBL] [Abstract][Full Text] [Related]
4. A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.
Santone M; Aprea S; Wu TY; Cooke MP; Mbow ML; Valiante NM; Rush JS; Dougan S; Avalos A; Ploegh H; De Gregorio E; Buonsanti C; D'Oro U
Hum Vaccin Immunother; 2015; 11(8):2038-50. PubMed ID: 26024409
[TBL] [Abstract][Full Text] [Related]
5. Delivering all in one: Antigen-nanocapsule loaded with dual adjuvant yields superadditive effects by DC-directed T cell stimulation.
Paßlick D; Piradashvili K; Bamberger D; Li M; Jiang S; Strand D; R Wich P; Landfester K; Bros M; Grabbe S; Mailänder V
J Control Release; 2018 Nov; 289():23-34. PubMed ID: 30219277
[TBL] [Abstract][Full Text] [Related]
6. Bridging Small Molecules to Modified Bacterial Microparticles Using a Disulphide Linkage: MIS416 as a Cargo Delivery System.
Mainini F; Larsen DS; Webster GA; Young SL; Eccles MR
PLoS One; 2015; 10(12):e0145403. PubMed ID: 26695183
[TBL] [Abstract][Full Text] [Related]
7. Polysaccharides from Ganoderma formosanum function as a Th1 adjuvant and stimulate cytotoxic T cell response in vivo.
Pi CC; Chu CL; Lu CY; Zhuang YJ; Wang CL; Yu YH; Wang HY; Lin CC; Chen CJ
Vaccine; 2014 Jan; 32(3):401-8. PubMed ID: 24252697
[TBL] [Abstract][Full Text] [Related]
8. Characterization of protein-adjuvant coencapsulation in microparticles for vaccine delivery.
Mathew S; Lendlein A; Wischke C
Eur J Pharm Biopharm; 2014 Jul; 87(2):403-7. PubMed ID: 24747810
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion.
Marincek BC; Kühnle MC; Srokowski C; Schild H; Hämmerling G; Momburg F
Mol Immunol; 2008 Nov; 46(1):181-91. PubMed ID: 18804283
[TBL] [Abstract][Full Text] [Related]
10. Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo.
Powell TJ; Palath N; DeRome ME; Tang J; Jacobs A; Boyd JG
Vaccine; 2011 Jan; 29(3):558-69. PubMed ID: 20951665
[TBL] [Abstract][Full Text] [Related]
11. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
12. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
13. Antigen delivery for cross priming via the emulsion vaccine adjuvants.
Shen SS; Yang YW
Vaccine; 2012 Feb; 30(9):1560-71. PubMed ID: 22230588
[TBL] [Abstract][Full Text] [Related]
14. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of structurally related peptidoglycan monomer and muramyl dipeptide on humoral IgG immune response to ovalbumin in mouse.
Habjanec L; Halassy B; Tomasić J
Int Immunopharmacol; 2010 Jul; 10(7):751-9. PubMed ID: 20403461
[TBL] [Abstract][Full Text] [Related]
16. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
17. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin.
Bomford R
Clin Exp Immunol; 1980 Feb; 39(2):435-41. PubMed ID: 6248283
[TBL] [Abstract][Full Text] [Related]
18. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
19. Immunoadjuvant efficacy of N-carboxymethyl chitosan for vaccination via dendritic cell activation.
Kim JJ; Nam JP; Nah JW; Jang MK; Yee ST
J Med Food; 2014 Feb; 17(2):268-77. PubMed ID: 24325456
[TBL] [Abstract][Full Text] [Related]
20. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
